Methods of using adipose tissue-derived cells in augmenting autologous fat transfer

• US 8,771,678 B2
• Filed: 08/17/2012
• Issued: 07/08/2014
• Est. Priority Date: 12/07/2001
• Status: Expired due to Term

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Cytori Therapeutics Incorporated
• Inventors: Fraser, John K., Hedrick, Marc H.
• Primary Examiner(s): Lankford, Blaine
• Application Number:
  US13/588,989
• Publication Number:
  US 20120308536A1
• Time in Patent Office: 690 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/426 Immunomodulating agents, i.e. cytokines, interleukins, interferons
• CPC Class Codes: A61L 2430/34 for soft tissue reconstruction
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 Vascular Endothelial cells

Abstract

Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.

Claims

1. A method of augmenting autologous fat transfer to a subject, comprising:

removing a first portion of adipose tissue that comprises a cell population comprising adipose-derived stem cells and progenitor from said subject;

introducing the removed adipose tissue into a self-contained cell processing unit configured to maintain a closed pathway;

isolating said cell population that comprises adipose-derived stem cells and progenitor cells from mature adipocytes and connective tissue present in the removed adipose tissue so as to obtain a substantially isolated cell population comprising disaggregated adipose-derived stem cells and progenitor cells, while maintaining a closed pathway;

concentrating said substantially isolated cell population comprising disaggregated adipose-derived stem cells so as to obtain a concentrated cell population that comprises disaggregated adipose-derived stem cells and progenitor cells, while maintaining a closed pathway;

mixing said concentrated cell population comprising adipose-derived stem cells and progenitor cells with a second portion of unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments obtained from said subject, so as to obtain an adipose tissue composition comprising a mixture of said concentrated cell population comprising disaggregated adipose-derived stem cells and progenitor cells and said unprocessed adipose tissue comprising intact, non-disaggregated tissue fragments tissue; and

reintroducing said adipose tissue composition into said subject.

2. The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a breast of the subject.

3. The method of claim 1, wherein said subject has radiation trauma.

4. The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a soft-tissue region of the subject.

5. The method of claim 4, wherein said soft tissue defect was from irradiation or war injury.

6. The method of claim 1, further comprising providing said mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells to a urethral region of the subject.

7. The method of claim 1, wherein multiple doses of the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells are provided to said subject.

8. The method of claim 1, further comprising providing one or more angiogenic factors to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells.

9. The method of claim 1, further comprising providing the one or more arteriogenic factors to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells.

10. The method of claim 1, further comprising providing one or more immunosuppressive drugs to the mixture of the unprocessed adipose-tissue and the concentrated cell population that comprises adipose-derived stem cells and progenitor cells.

11. The method of claim 1, further comprising culturing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells prior to mixing said cell population that comprises adipose-derived stem cells with said second portion of unprocessed adipose tissue comprising intact, non disaggregated tissue fragments from said subject.

12. The method of claim 11 wherein said culturing step comprises exposing said concentrated cell population that comprises adipose-derived stem cells and progenitor cells to culture conditions that promote differentiation towards an endothelial phenotype.

13. The method of claim 11, wherein said culturing step is performed on a scaffold.

14. The method of claim 13, wherein said scaffold is resorbable in vivo.